University of Leicester researcher in potential medical breakthrough
“This new drug could be a game changer for future treatment of asthma” – Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester
The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.
The research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as “a game changer for future treatment of asthma.”
Three people die every day because of asthma attacks and research shows that two thirds of asthma deaths are preventable, according to Asthma UK.
Fevipiprant (QAW039) significantly decreased the symptoms of asthma, improved lung function, reduced inflammation and repaired the lining of airways.
The drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma, according to ClinTrials.gov.
A total of 61 people took part in the research. One group was given 225mg of the drug twice a day for 12 weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking.
The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.
The sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.
People who do not have asthma have a percentage of less than one and those with moderate-to-severe asthma typically have a reading of about five per cent.
The rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.
Professor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.
Professor Brightling said: “A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.
“Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.
“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.
“This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a ‘game changer’ for future treatment.”
Gaye Stokes from Grantham in Lincolnshire has had severe asthma for 16 years. She took part in the trial and was part of the Fevipiprant group.
The 54-year-old said: “I knew straight away that I had been given the drug. I felt like a completely different person. I had more get up and go, I was less wheezy and for the first time in years I felt really, really well.
“For me, it felt like a complete wonder drug and I can’t wait for it to be available because I really think it could make a huge difference to me.”
After the 12 week trial and Gaye stopped receiving the drug, she said her health started to “go downhill again very quickly”.
Professor Brightling added that the latest advance underpinned the work of the Leicester Precision Medicine Institute, a Centre of Excellence that coalesces and aligns the research missions of the University of Leicester and the NHS in Leicester.
Future treatment of human disease will increasingly move from a ‘one size fits all’ approach to one of tailoring the treatment to the individual patient.
Asthma is a long-term condition that affects the airways. When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.
The NIHR Leicester Respiratory Biomedical Research Unit – a partnership between the University of Leicester and Leicester’s Hospitals – focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).
The Latest on: Asthma pill
via Google News
The Latest on: Asthma pill
- Coronavirus and Asthma: 9 Things You Need to Know, According to a Doctoron March 23, 2020 at 9:13 am
If you do have severe asthma, you may be in the 'high risk' group of people being asked to take part in 'shielding' – staying at home at all times for a minimum of 12 weeks, with no visitors (this ...
- Coronavirus with asthma: What the CDC says you should know if you have asthma during COVID-19 pandemicon March 21, 2020 at 8:16 pm
Those with asthma may be at a higher risk of getting very sick from COVID-19, according to the Centers for Disease Control and Prevention. The CDC put out guidelines for those with the respiratory ...
- Asthma Patients: Stay on Steroids in Face of COVID-19, Say Expertson March 20, 2020 at 1:29 pm
"If a patient has asthma they need to stay on their preventive asthma medication, which in most cases would include inhaled corticosteroids," Blaiss, who is also clinical professor of pediatrics at ...
- How does coronavirus affect asthma sufferers?on March 20, 2020 at 11:06 am
If you suffer from asthma, you may be wondering: How could the novel coronavirus, known as COVID-19, affect you differently? It’s well known that other respiratory conditions, such as the common cold ...
- Planned primary health care asthma contacts during 12-year follow-up after Finnish National Asthma Programme: focus on spirometryon March 20, 2020 at 3:07 am
Primary health care (PHC) providers are at the front line of asthma management. To evaluate how planned asthma follow-up occurred in PHC and whether lung function tests were used, 203 patients were ...
- People with asthma and COPD assured there's no need to stockpile medicineon March 20, 2020 at 1:14 am
PEOPLE WITH RESPIRATORY conditions are being assured that there is no shortage of medication for their conditions and that stockpiling isn’t necessary. The Asthma Society of Ireland is today assuring ...
- Independent risk factors for death in patients admitted for asthma exacerbation in Taiwanon March 19, 2020 at 3:15 am
The independent risk factors for death in patients admitted for asthma exacerbation have not been thoroughly investigated. This study aimed to investigate these independent risk factors and the ...
- Asthma Therapeutics Market Is Expected To Reach US$ 23.4Bn by 2024 | Credence Researchon March 19, 2020 at 1:41 am
The latest market report published by Credence Research, Inc. "Global Asthma Therapeutics Market- Growth, Future Prospects and Competitive Analysis, 2016 - 2024" the global asthma therapeutics market ...
- AAAAI: Pediatric Asthma Highlightson March 18, 2020 at 11:02 am
Rodriguez did not observe a link between stressors and slowed activity, exercise-related symptoms, or the use of asthma rescue medication. Rhinitis Adds to Asthma Morbidity In abstract #364, ...
- Are There Home Remedies for an Asthma Attack?on March 18, 2020 at 10:18 am
The caffeine in black or green tea and coffee is believed to help treat asthma. It works similarly to the popular asthma medication theophylline, which opens up the airways. A 2010 research review, ...
via Bing News